Menu
Search
|

Menu

Close
X

Oasmia Pharmaceutical AB OASM.OQ (NASDAQ Stock Exchange Capital Market)

4.88 USD
-0.17 (-3.37%)
As of Nov 16
chart
Previous Close 5.05
Open 4.92
Volume 1,745
3m Avg Volume 14,302
Today’s High 4.99
Today’s Low 4.83
52 Week High 5.70
52 Week Low 0.85
Shares Outstanding (mil) 194.39
Market Capitalization (mil) 2,857.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, SEK)
FY19
0
FY18
3
FY17
0
FY16
6
FY15
2
EPS (SEK)
FY19
-0.176
FY18
-0.777
FY17
-1.389
FY16
-1.371
FY15
-1.276
*Note: Units in Millions of Swedish Krona
**Note: Units in Swedish Krona

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
871.74
20.58
Price to Book (MRQ)
vs sector
8.19
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
52.34
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-32.26
13.58
Return on Equity (TTM)
vs sector
-32.26
15.11

EXECUTIVE LEADERSHIP

Julian Aleksov
Executive Chairman of the Board, Since 2017
Salary: 1,698,000.00kr
Bonus: 23,000.00kr
Mikael Asp
Chief Executive Officer, Since 2015
Salary: 1,366,000.00kr
Bonus: --
Anders Blom
Acting Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Magdalena Berg
Head of Accounting, Since
Salary: --
Bonus: --
Dzianis Babrou
Head of Product Development, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Vallongatan 1
UPPSALA     752 28

Phone: +4618.505440

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. Its drugs portfolio comprises six candidates: Paclical, Doxophos, Docecal and OAS-19, which are implemented in human treatment, as well as Paccal Vet-CA1 and Doxophos Vet, introduced in cancer in dogs. The Company’s medicines are based on the patented XR-17 excipient, which forms micelles with water-soluble substances. Furthermore, It cooperates with Abbott Laboratories, Pharmasyntez, Nippon Zenyaku Kogyo and Medison Pharma. The Company is a parent of Oasmia Global Supplies AB and Oasmia Animal Health AB.

SPONSORED STORIES